



US009511020B2

(12) **United States Patent**  
**Lichter et al.**(10) **Patent No.:** **US 9,511,020 B2**(45) **Date of Patent:** **\*Dec. 6, 2016**(54) **CONTROLLED RELEASE  
CORTICOSTEROID COMPOSITIONS AND  
METHODS FOR THE TREATMENT OF OTIC  
DISORDERS**(71) Applicants: **Otonomy, Inc.**, San Diego, CA (US);  
**The Regents of the University of  
California**, Oakland, CA (US)(72) Inventors: **Jay Lichter**, Rancho Santa Fe, CA  
(US); **Andrew M. Trammel**, Olathe,  
KS (US); **Fabrice Piu**, San Diego, CA  
(US); **Qiang Ye**, San Diego, CA (US);  
**Luis A. Dellamary**, San Marcos, CA  
(US); **Carl Lebel**, Malibu, CA (US);  
**Jeffrey P. Harris**, La Jolla, CA (US)(73) Assignees: **Otonomy, Inc.**, San Diego, CA (US);  
**The Regents of the University of  
California**, Oakland, CA (US)( \* ) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.This patent is subject to a terminal dis-  
claimer.(21) Appl. No.: **14/795,819**(22) Filed: **Jul. 9, 2015**(65) **Prior Publication Data**

US 2015/0313838 A1 Nov. 5, 2015

**Related U.S. Application Data**(60) Continuation of application No. 14/300,030, filed on  
Jun. 9, 2014, which is a continuation of application  
No. 13/190,330, filed on Jul. 25, 2011, now Pat. No.  
8,828,980, which is a division of application No.  
12/466,310, filed on May 14, 2009, now Pat. No.  
8,030,297.(60) Provisional application No. 61/127,713, filed on May  
14, 2008, provisional application No. 61/060,425,  
filed on Jun. 10, 2008, provisional application No.  
61/074,583, filed on Jun. 20, 2008, provisional  
application No. 61/094,384, filed on Sep. 4, 2008,  
provisional application No. 61/101,112, filed on Sep.  
29, 2008, provisional application No. 61/140,033,  
filed on Dec. 22, 2008, provisional application No.  
61/095,248, filed on Sep. 8, 2008, provisional  
application No. 61/087,940, filed on Aug. 11, 2008,  
provisional application No. 61/082,450, filed on Jul.  
21, 2008.(30) **Foreign Application Priority Data**

Dec. 22, 2008 (GB) ..... 0823378.5

(51) **Int. Cl.****A61K 31/573** (2006.01)  
**A61K 47/10** (2006.01)  
**A61K 9/00** (2006.01)**A61K 9/06** (2006.01)**A61K 45/06** (2006.01)(52) **U.S. Cl.**CPC ..... **A61K 9/0046** (2013.01); **A61K 9/06**  
(2013.01); **A61K 31/573** (2013.01); **A61K**  
**45/06** (2013.01); **A61K 47/10** (2013.01)(58) **Field of Classification Search**CPC ..... **A61K 31/573**; **A61K 47/10**; **A61K 45/06**;  
**A61K 9/06**; **A61K 9/0046**

See application file for complete search history.

(56) **References Cited**

## U.S. PATENT DOCUMENTS

4,188,373 A 2/1980 Krezanoski  
4,478,822 A 10/1984 Haslam et al.  
4,968,507 A 11/1990 Zentner et al.  
5,292,516 A 3/1994 Viegas et al.  
5,503,848 A 4/1996 Perbellini et al.  
5,861,174 A 1/1999 Stratton et al.  
6,177,434 B1 1/2001 Kopke et al.  
6,201,065 B1 3/2001 Pathak et al.  
6,239,113 B1 5/2001 Dawson et al.  
6,284,804 B1 9/2001 Singh et al.  
6,316,011 B1 11/2001 Ron et al.  
6,359,016 B2 3/2002 Singh et al.  
6,392,036 B1 5/2002 Karlsson et al.  
6,488,952 B1 12/2002 Kennedy et al.  
6,509,327 B1 1/2003 Cagle et al.  
6,548,527 B2 4/2003 Rahman et al.

(Continued)

## FOREIGN PATENT DOCUMENTS

CN 101664381 A 3/2010  
EP 0551626 A1 7/1993

(Continued)

## OTHER PUBLICATIONS

Chen et al. In vivo Distribution and Pharmacokinetics of  
Dexamethasone Acetate Nanoparticles Thermosensitive in situ Gel  
Following Intratympanic Injection. Chin. J. Otorhinolaryngol Head  
Neck Surg 42:533-534 (2007).Chen et al. Preliminary study on brain-targeted drug delivery via  
inner ear. Acta Pharmaceutica Sinica 42:1102-1106 (2007) (English  
Abstract).Feng et al., Effect of Poloxamer 407 on the cochlear orphology and  
hearing function after perfusion in round window: experiment with  
guinea pigs. National Medical Journal of China 87:2289-2291  
(2007) (English Translation).

(Continued)

*Primary Examiner* — Sarah Pihonak(74) *Attorney, Agent, or Firm* — Wilson, Sonsini,  
Goodrich & Rosati

(57)

**ABSTRACT**Disclosed herein are compositions and methods for the  
treatment of otic disorders with steroid, NSAID, and/or  
adenosine triphosphatase ("ATPase") modulator agents. In  
these methods, the steroidal, NSAID, and/or ATPase com-  
positions and formulations are administered locally to an  
individual afflicted with an otic disorder, through direct  
application of these compositions and formulations onto or  
via perfusion into the targeted auris structure(s).**8 Claims, 10 Drawing Sheets**